(19)
(11) EP 1 259 240 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.05.2007 Bulletin 2007/19

(45) Mention of the grant of the patent:
05.07.2006 Bulletin 2006/27

(21) Application number: 01900231.0

(22) Date of filing: 09.01.2001
(51) International Patent Classification (IPC): 
A61K 31/455(2006.01)
A61P 17/00(2006.01)
 A61K 31/7004(2006.01)
(86) International application number:
PCT/IL2001/000017
(87) International publication number:
WO 2001/051051 (19.07.2001 Gazette 2001/29)

(54)

AGENTS, SUCH AS NICOTINAMIDE OR CADPR FOR THE TREATMENT OF SKIN DISORDERS

MITTEL, WIE NIKOTINAMIDE ODER CADPR ZUR BEHANDLUNG VON HAUTKRANKHEITEN

Agents de traitement des troubles cutanés, tel le nicotinamide et le cADPR

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 11.01.2000 IL 13397600

(43) Date of publication of application:
27.11.2002 Bulletin 2002/48

(73) Proprietor: DERMIPSOR LTD
12 900 Katzrin (IL)

(72) Inventors:
  • Harel, Avikam
    69492 Tel Aviv (IL)
  • Bloch, Olga
    49473 Petach Tikva (IL)

(74) Representative: Schmitz, Jean-Marie et al
Dennemeyer & Associates S.A. P.O. Box 1502
1015 Luxembourg
1015 Luxembourg (LU)


(56) References cited: : 
EP-A- 0 052 705
DE-A- 4 335 454
 WO-A-98/52529
DE-U- 29 916 231
   
  • DATABASE WPI Derwent Publications Ltd., London, GB; AN 1994-170436 XP002183599 FORGACS ET AL: & HU 209 067 B (TATAR J), 28 March 1994 (1994-03-28)
  • MORIMOTO ET AL: "an open study of vitamin D3 treatment in psoriasis vulgaris" BRITISH JOURNAL OF DERMATOLOGY, vol. 115, 1986, pages 421-429, XP000905334 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).